pantoprazole and dexlansoprazole

pantoprazole has been researched along with dexlansoprazole in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (75.00)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T1
Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH1
Goh, KL; Zou, D1
Li, MJ; Li, Q; Liu, LQ; Sun, M1
Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM1
Lespessailles, E; Toumi, H1
Lee, WP1

Reviews

5 review(s) available for pantoprazole and dexlansoprazole

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome

2014
East Asian perspective on the interaction between proton pump inhibitors and clopidogrel.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anticoagulants; Asia, Eastern; Asian People; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Dexlansoprazole; Drug Interactions; Drug Therapy, Combination; Gastroesophageal Reflux; Gastrointestinal Hemorrhage; Humans; Isoenzymes; Pantoprazole; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Ticlopidine

2017
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
    Medicine, 2017, Volume: 96, Issue:39

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration

2017
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
    International journal of molecular sciences, 2022, 09-14, Volume: 23, Issue:18

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States

2022

Other Studies

3 other study(ies) available for pantoprazole and dexlansoprazole

ArticleYear
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity

2012
Qualimetric analysis of proton pump inhibitors in Ukraine.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2019, Volume: 72, Issue:9 cz 2

    Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine

2019
Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors.
    Journal of the Chinese Medical Association : JCMA, 2022, 09-01, Volume: 85, Issue:9

    Topics: Activating Transcription Factor 6; Dexlansoprazole; Endoplasmic Reticulum Stress; Esomeprazole; Humans; Pantoprazole; Protein Serine-Threonine Kinases; Proton Pump Inhibitors; Rabeprazole; Reactive Oxygen Species; Stomach Neoplasms; Superoxide Dismutase; Vacuolar Proton-Translocating ATPases

2022